MAIA Biotechnology activates first U.S. site for Phase 2 THIO-101 lung cancer trial
MAIA Biotechnology said it activated its first U.S. clinical site, Summit Medical Group in New Jersey, for the expansion of its Phase 2 THIO-101 trial of ateganosine in third-line non-small cell lung cancer. The company plans four more U.S. sites in 2026, and the U.S. portion of third-line testing is funded by a $2.3 million NIH grant; the filing reports no financial results or guidance.
Key points
- First U.S. site activated: Summit Medical Group in New Jersey, with principal investigator Charles J. Kim, M.D.
- MAIA intends to open four additional U.S. sites in 2026.
- U.S. third-line evaluation is funded by a $2.3 million grant from the National Institutes of Health.
- Trial is ongoing in Europe and Asia with 44 active sites in 6 countries.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.